Tradestie Institutional Equity Comparison Engine
CING vs SRZN โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
SRZN Overall Edge
SRZN Captures Institutional Edge (3โ0 Pillars ยท 5โ2 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Surrozen, Inc. Common (SRZN) driven by superior Growth & Margin, Momentum & Technical, Options & Structure. Fundamentally, CING trades at N/M Forward P/E with 0.0% operating margin (+0.0% YoY revenue) versus SRZN at N/M Forward P/E and -485.4% operating margin (+408.6% YoY). In options structure, CING sits in BREAKDOWN (16th %ile IV; Dealer Gamma Walls on Pro) against SRZN sits in CONSOLIDATION (5th %ile IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
CING N/M vs SRZN N/M Fwd P/E
Growth & Margin Winner
SRZN
Op Margin 0.0% vs -485.4% ยท YoY +0.0% vs +408.6%
Momentum & Technical Winner
SRZN
1Y +36.4% vs +132.4% ยท 52W Pos 18% vs 70%
Options & Structure Winner
SRZN
BREAKDOWN (16th %ile IV) vs CONSOLIDATION (5th %ile IV)
CING
NASDAQ
Cingulate Inc. Common Stock
Pharmaceutical Preparations
$4.76
+26.93% 1D
Market Cap
$62.5M
1M Return
+9.17%
1Y Return
+36.39%
Forward P/E
N/M
Unified AI Score
44.8 / 100
HOLD
Tech 31.0
Fund 50.0
Flow 67.0
Mom 60.0
SRZN
NASDAQ
Surrozen, Inc. Common
Biological Products, (No Disgnostic Substances)
$30.16
-6.68% 1D
Market Cap
$602.5M
1M Return
+26.51%
1Y Return
+132.36%
Forward P/E
N/M
Unified AI Score
33.2 / 100
SELL
Tech 50.0
Fund 34.0
Flow 65.0
Mom 40.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
CING +36.39%
SRZN +132.36%
Spread: +95.97 pp (SRZN Lead)
Pillar 3 Operating Profitability Benchmark (Trailing 12-Month)
CING TTM Op. Margin: 0.0%
SRZN TTM Op. Margin: -485.4%
Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on CING vs SRZN. Trailing 12-month operating profitability (CING 0.0% vs SRZN -485.4%) and valuation multiples (CING N/M vs SRZN N/M Forward P/E) are benchmarked directly in Pillar 4 below.
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | CING | SRZN | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $62.5M | $602.5M | Larger Scale | SRZN |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +0.0% | +408.6% | Higher Growth | SRZN |
| Operating Margin (TTM) Profitability | 0.0% | -485.4% | Higher Margin | CING |
| Net Profit Margin Profitability | 0.0% | 0.0% | Higher Margin | Tie |
| Return on Equity (ROE) Capital Efficiency | -198.7% | -62.8% | Higher ROE | SRZN |
| 52-Week Range Position Momentum | 18% ($3โ$12) | 70% ($12โ$38) | Stronger Trend | SRZN |
| Beta / 30D Volatility Risk Regime | 1.13ฮฒ ยท 117% Vol | 1.28ฮฒ ยท 70% Vol | Lower Realized Risk | SRZN |
| Unified Institutional Score Composite Signal | 44.8 / 100 (HOLD) | 33.2 / 100 (SELL) | Higher Composite | CING |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full CING vs SRZN Buy Guide
CING
BREAKDOWN
170d in phase ยท OBV ACCUMULATION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
16th %ile
IV Regime
Compressed (<25th %ile)
SRZN
CONSOLIDATION
38d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
5th %ile
IV Regime
Compressed (<25th %ile)
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither CING nor SRZN registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.